Targeting the Ghrelin System: Multiple Strategies to Treat Obesity and Metabolic Disease
Review of ghrelin-GHSR targeted strategies for obesity treatment including ghrelin antibodies, RNA spiegelmers, GHSR antagonists/inverse agonists, and GOAT inhibitors — multiple approaches to suppress the hunger hormone system.
Quick Facts
What This Study Found
Ghrelin-GHSR targeting strategies include ghrelin-neutralizing antibodies/spiegelmers, GHSR antagonists/inverse agonists, GOAT enzyme inhibitors, and approaches to decrease ghrelin synthesis. Animal efficacy demonstrated for multiple compounds.
Key Numbers
Ghrelin: 28 amino acids; secreted by gastric X/A cells; endogenous GHSR ligand
How They Did This
Narrative review of therapeutic strategies targeting the ghrelin-GHSR pathway for obesity and metabolic diseases.
Why This Research Matters
Ghrelin is the only known circulating appetite-stimulating hormone. Blocking it complements GLP-1 drugs (which enhance satiety), potentially enabling combination therapy for greater weight loss.
The Bigger Picture
Ghrelin blockade and GLP-1 activation are complementary anti-obesity mechanisms. Combining both could achieve weight loss approaching surgical levels.
What This Study Doesn't Tell Us
Mostly preclinical compounds. No ghrelin-targeting drugs approved for obesity. Safety of chronic hunger hormone suppression unclear.
Questions This Raises
- ?Would combining ghrelin blockade with GLP-1 agonists produce superior weight loss?
- ?Which approach is closest to clinical approval?
- ?Are there safety concerns with chronic ghrelin suppression?
Trust & Context
- Key Stat:
- 5+ blocking strategies Multiple approaches to suppress ghrelin hunger signaling are in development, each with unique advantages for obesity treatment
- Evidence Grade:
- Not applicable (narrative review). Based on preclinical data.
- Study Age:
- Published 2021. Ghrelin-targeting continues alongside GLP-1 drugs.
- Original Title:
- Ghrelin Based Therapy of Metabolic Diseases.
- Published In:
- Current medicinal chemistry, 28(13), 2565-2576 (2021)
- Authors:
- Liang, Yuan(2), Yin, Wenzhen, Yin, Yue(2), Zhang, Weizhen
- Database ID:
- RPEP-05554
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why not just block ghrelin to stop hunger?
Multiple approaches are being developed, but ghrelin also protects against low blood sugar and has other functions. The right balance of suppression needs to be found.
How would this compare to Ozempic?
GLP-1 drugs enhance satiety. Ghrelin blockers reduce hunger. Combining both could theoretically produce greater appetite control than either alone.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05554APA
Liang, Yuan; Yin, Wenzhen; Yin, Yue; Zhang, Weizhen. (2021). Ghrelin Based Therapy of Metabolic Diseases.. Current medicinal chemistry, 28(13), 2565-2576. https://doi.org/10.2174/0929867327666200615152804
MLA
Liang, Yuan, et al. "Ghrelin Based Therapy of Metabolic Diseases.." Current medicinal chemistry, 2021. https://doi.org/10.2174/0929867327666200615152804
RethinkPeptides
RethinkPeptides Research Database. "Ghrelin Based Therapy of Metabolic Diseases." RPEP-05554. Retrieved from https://rethinkpeptides.com/research/liang-2021-ghrelin-based-therapy-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.